Analyst Ratings January 29, 2026

Goldman Lowers Las Vegas Sands Target as Macau Softness Offsets Singapore Strength

Bank trims price objective to $73 but keeps a Buy stance after mixed regional results and strong quarterly beats

By Avery Klein LVS
Goldman Lowers Las Vegas Sands Target as Macau Softness Offsets Singapore Strength
LVS

Goldman Sachs reduced its 12-month price target for Las Vegas Sands to $73 from $80 while retaining a Buy rating, citing divergent performance across the operator's regional businesses. Singapore outperformed expectations, but Macau fell short of estimates and saw margin pressure. The company also reported a quarterly earnings and revenue beat for Q4 2025.

Key Points

  • Goldman Sachs cut LVS price target to $73 from $80 but maintained a Buy rating (Markets: equities, Financials).
  • Singapore outperformed with EBITDA of $806M ($761M hold adjusted) versus $692M consensus and is viewed as the primary growth lever toward >$3B EBITDA by 2026 (Sectors: gaming, hospitality).
  • Macau missed expectations with EBITDA of $608M ($582M hold adjusted) versus $625M consensus and saw margin pressure from higher promotional allowances and operating costs (Sectors: gaming, travel).

Goldman Sachs has reduced its price target on Las Vegas Sands (LVS) to $73.00 from $80.00, while leaving its Buy rating intact. The revised objective sits near InvestingPro's Fair Value assessment and reflects a mixed read on the company's regional operations following its latest results.

Investors should note that the stock still appears slightly undervalued against that Fair Value metric despite trading at a price-to-earnings ratio of 27.9. InvestingPro classifies the company's overall financial health as "GOOD," and Las Vegas Sands reported robust gross profit margins of 79.8% over the last twelve months.

Regional performance in the most recent quarter diverged. Singapore was a clear outperformer, delivering EBITDA of $806 million - or $761 million on a hold-adjusted basis - comfortably above the consensus estimate of $692 million. That strength underpins Goldman Sachs' view that Singapore could be on a path to exceed $3 billion in EBITDA by 2026 and creates scope for incremental share repurchases.

By contrast, Macau missed expectations. Reported EBITDA for Macau came in at $608 million - $582 million on a hold-adjusted basis - below the consensus forecast of $625 million. The Macau business also recorded margins at their weakest levels since reopening, a development the company attributed to higher promotional allowances and increased operating expenses.

Goldman Sachs highlighted the combination of these trends in explaining the target reduction. The firm pointed to continued upside in Singapore but warned that Macau faces a more challenging backdrop, with tougher second-half year-over-year comparisons approaching. Those dynamics, Goldman says, could leave the stock trading in a range in the near term despite the Buy rating.

Separately, Las Vegas Sands reported a solid fourth-quarter showing for 2025, exceeding consensus on both earnings and revenue. The company posted earnings per share of $0.85 versus the $0.77 estimate, and revenue of $3.65 billion against expectations for $3.33 billion. Those results underline that the company beat market forecasts for the quarter.

Overall, the adjustment in Goldman Sachs' price objective reflects a balance: meaningful momentum in Singapore that could drive material EBITDA gains and shareholder returns, set against Macau headwinds that have compressed margins and could pressure near-term stock performance. Market participants will be watching how Macau trends evolve through the rest of the year and whether Singapore's trajectory translates into the higher EBITDA Goldman envisions.


Summary

Goldman Sachs trimmed its price target on Las Vegas Sands to $73 while maintaining a Buy rating. The move follows mixed quarterly results: Singapore outperformed expectations while Macau underperformed and saw margin deterioration. The company also reported Q4 2025 earnings and revenue above consensus.

Key points

  • Goldman Sachs lowered its price target on LVS to $73 from $80 but kept a Buy rating (Markets: equities, Financials).
  • Singapore delivered EBITDA of $806 million ($761 million hold adjusted), above the $692 million consensus; Goldman projects a path to over $3 billion in EBITDA by 2026 and possible increased buybacks (Sectors: gaming, hospitality).
  • Macau reported EBITDA of $608 million ($582 million hold adjusted), below the $625 million consensus, with margins the weakest since reopening due to higher promotional allowances and operating expenses (Sectors: gaming, travel).

Risks / Uncertainties

  • Macau's softer-than-expected results and compressed margins may weigh on near-term performance and keep the stock range-bound - impacting gaming and hospitality sectors.
  • Tougher second-half year-over-year comparisons in Macau could further constrain earnings momentum and investor sentiment for LVS - relevant to travel and leisure markets.
  • Elevated promotional allowances and rising operating expenses in Macau are squeezing margins, introducing uncertainty around near-term profitability - implications for casino operators and regional service providers.

Risks

  • Macau weakness and margin compression could keep LVS shares trading in a narrow range near term, affecting investor returns (Impacted sectors: gaming, hospitality).
  • Tougher second-half year-over-year comparisons in Macau may limit upside to earnings in the near future (Impacted sectors: travel, leisure).
  • Sustained increases in promotional allowances and operating expenses in Macau introduce further uncertainty around profitability (Impacted sectors: casino operators, regional services).

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026